Board of Directors
David Martyr
Chairman
With a career spanning nearly 40 years in lasers, optics, microscopy, life sciences and healthcare, David studied engineering at university and gained his PhD in the application of high-power lasers for materials processing. Following several management appointments in the laser industry, he joined Leica Microsystems where he ultimately became CEO for 5 years. Earlier at Leica Microsystems he led their confocal laser microscopy business. David was a VP in Danaher, responsible for Life Science and Diagnostics, and more recently was CEO at Tecan for 7 years, a market leading Swiss listed company developing automated robotic workstations and imaging systems for Life Science and Diagnostic applications.
Today, David is Chairman of Sebia Diagnostics (FR); BBI Solutions (UK); Rayner Intra-Ocular Lenses (UK); a member of the Novo Advisory Group of Novo Holdings (DK) and a board member of LRE Medical (DE).
Renato Giacobbo Scavo
CEO
A seasoned entrepreneur and investor with over 20 years of experience in Venture Capital and Private Equity-backed industries. Renato holds a degree in Electronic Engineering from the University of Rome and an MBA from HEC Paris. Following key managerial roles at TIM and Bain & Company—where he focused on innovation and scale-ups—he became a serial founder in 2007, achieving several successful exits across High-Tech sectors, including AI, Hardware, and Industrial Design.
An early stage investor and Board Director of CrestOptics since 2013, he has served as the company’s CEO since 2020.
Rodrigo Bianchi
Rodrigo is a Senior Global Executive in the Medical Device Industry with over 30 years of experience in some of the most important Medical Devices companies.
He started his career at Procter & Gamble and in 1987 he joined Johnson&Johnson where he covered several roles including: President Worldwide DePuy Mitek (2001-2003) and President Worldwide Ethicon (2004-2005).
From 2013 to 2019 Mr. Bianchi was part of Smith&Nephew where he served as President International Markets. He holds a bachelor’s degree in Economics from Rome University and a Master in Business Administration from Luiss Business School in Rome.
Alessandro Maria Cremona
Senior Executive with over 25 years of leadership in the banking and corporate governance sectors. His career is highlighted by his tenure at Nomura Italia SpA, where he served as CEO and Head of Investment Banking (1992–2010), spearheading strategic capital market operations and consolidating the firm’s presence in the Italian market.
Currently, Alessandro is the Chairman and CEO of D-TAILS (since 2023, following his role as Chairman since 2021), a life-science spin-off of CrestOptics focused on advanced diagnostics. He also serves as Chairman of Goldmann & Partners, a B Corp-certified benefit corporation specializing in bioclimatic architecture and sustainable consultancy. He is a Non-Executive Director at SoGeMi S.p.A. (owned by the Municipality of Milan), overseeing the strategic management of Milan’s wholesale food markets.
He holds a Degree in Physics from the University of Milan, completed a research period at the University of Oregon, and earned an MBA with Honors from SDA Bocconi. His professional profile uniquely bridges a rigorous scientific background with deep expertise in corporate finance, ESG governance, and industrial innovation.
Lauren Edison
Lauren joined Apposite in 2018 from Jefferies’ Healthcare Investment Banking team. At Apposite she is a member of the investment team and works closely with management teams on business building through strategy, business development, M&A and debt and equity financing. In particular she is or has been involved in Apposite’s investments in 1MED, Emblation, Mirada Medical and MC Care Holdings. During her time at Jefferies, she advised on buy-side and sell-side mandates, product licensing and public capital raises across a variety of healthcare sub-sectors including dental, nanomedicine, biopharma, children’s services and pharma services. Lauren has a BA in Psychology and Philosophy from Oxford University.
Carlo Vanoli
Graduated Chemical Engineer (Milan Politecnico). Begins its career as Process and project engineer in the Chemical industry. BU director of one of the affiliates of Snia BPD group (diversified industrial conglomerate).
Senior Management Consultant in McKinsey and Co. Executive VP in Sorin Biomedica group, responsible for M&A activity (around 10 deals, worth in excess of € 1,5 Bn. CEO of Sorin Biomedical Inc. (Irvine, CA).
Past Member of the Board in several private and listed (in Italy and US) companies
Founder and Chairman of Medeor Associates srl (professional firm specialized in advisory and investment in Health Care). Manager, Board member and investor in more than 10 deals (Medtech, Pharma, HC Services) worth in aggregate more than € 1 Bn.
Partner in Heath and Primo Health Private Equity funds.
Currently board member in Corcym SA (CH), Aortic Lab (Italy), MT Ortho (Italy), CrestOptics (Italy), Medeor Capital (Italy)
David Porter
David brings over 30 years of experience in private equity, with a long track record of board leadership and investment across the healthcare sector. He has served on the boards of Habitus, MC Care Holdings, NIMGenetics, Swanton Care, CancerPartnersUK, Ulthera, Zonare, and Xthetix.
Before co‑founding Apposite in 2006, David worked on several major leveraged buyouts within Nomura’s Principal Finance Group and went on to establish and lead Nomura International’s healthcare investment and corporate finance teams. He has also held CEO roles in multiple organisations, including CLF Municipal Bank, an authorised bank.
Deeply engaged in the UK healthcare landscape, David has contributed to national policy discussions through his roles with the UK government’s Health Reform Group and the London Health Commission. He holds a degree in Chemistry from Oxford University.
Klaus Lun
With over two decades of experience in the life science, biotech, and diagnostics industries, Klaus is a seasoned leader and strategist dedicated to driving growth, innovation, and value creation. He embarked on his career journey at a small startup, then gained extensive experience during his tenure at Danaher, serving as the VP of Global Product Marketing at Molecular Devices and as Director of Business Development at Leica Microsystems. Today, Klaus is leading Tecan’s Life Science Division, a market-leading Swiss-listed company that specializes in developing automated robotic workstations and imaging systems for Life Science and Diagnostic applications.
Klaus holds a PhD in Neurobiology from the University of Heidelberg and earned an MBA from the University of Mannheim.
